帕纳替尼联合hyper-CVAD方案一线治疗费城染色体阳性急性淋巴细胞白血病:80个月随访结果
该研究在86例新诊断的费城染色体阳性急性淋巴细胞白血病成人患者中评估帕纳替尼联合hyper-CVAD方案。中位随访80个月,估计6年无事件生存率为65%,总生存率为75%,累积完全分子学缓解率为86%。长期结果继续显示优异疗效和可接受的安全性,表明该策略是Ph阳性ALL的另一种标准治疗方案。
要点
- 86例初治Ph阳性ALL成人接受帕纳替尼联合hyper-CVAD方案,中位年龄46岁(范围21-80岁)。
- 累积完全分子学缓解率为86%,估计6年无事件生存率65%、总生存率75%。
- 23%(20例)患者接受异基因造血干细胞移植,首次完全缓解时是否移植对结局无差异。
核心结论
- 帕纳替尼联合hyper-CVAD方案的长期结果继续显示优异的结局和可接受的安全性数据,表明该策略是Ph阳性ALL一线治疗的另一种标准治疗方案。
研究设计与样本
- 研究纳入86例新诊断的Ph阳性ALL成人患者,接受hyper-CVAD方案联合帕纳替尼治疗,中位随访80个月(范围16-129个月)。
- 帕纳替尼在诱导期45 mg每日一次×14天,之后45 mg每日一次持续(前37例)或30 mg每日一次持续,达到完全分子学缓解后减至15 mg每日一次。
- 维持治疗为每日帕纳替尼联合长春新碱-泼尼松每月一次共2年,之后每日帕纳替尼无限期使用;中枢神经系统预防为12次鞘内注射阿糖胞苷与甲氨蝶呤交替。
主要发现
- 68例治疗开始时存在活动性疾病的患者全部达到完全缓解。
- 累积完全分子学缓解率为86%。
- 20例(23%)患者接受异基因造血干细胞移植,首次完全缓解时是否移植对结局无差异。
- 中位随访80个月(范围16-129个月),估计6年无事件生存率为65%,总生存率为75%。
- 常见3-5级不良事件包括感染(n=80,93%)、肝转氨酶升高(n=26,31%)和总胆红素升高(n=13,15%)、高血压(n=15,17%)、胰腺炎(n=13,15%)、出血(n=12,13%)和皮疹(n=9,10%)。
关键数值与推荐
- 完全分子学缓解定义为定量逆转录聚合酶链反应检测BCR::ABL1转录本在0.01%灵敏度下不可测。
- 前37例患者中发生2例帕纳替尼相关心肌梗死死亡(3%;分别在第2.6个月和第4.3个月;均处于完全缓解),导致上述帕纳替尼剂量调整,之后未再观察到帕纳替尼相关死亡。
临床怎么用
- 作者认为帕纳替尼联合hyper-CVAD策略是Ph阳性ALL一线治疗的另一种标准治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combination of ponatinib, a third-generation BCR::ABL1 tyrosine kinase inhibitor, with hyper-CVAD chemotherapy resulted in high rates of complete molecular remissions and survival, without the need for stem cell transplantation (SCT) in most patients with Philadelphia chromosome(Ph)-positive acute lymphocytic leukemia (ALL). Confirming these results in a large cohort of patients with longer follow-up would establish this regimen as a new standard of care. Adults with newly diagnosed Ph-positive ALL were treated with the hyper-CVAD regimen. Ponatinib was added as 45 mg daily × 14 during induction, then 45 mg daily continuously (first 37 patients) or 30 mg daily continuously, with dose reduction to 15 mg daily upon achievement of a complete molecular response (CMR; absence of a detectable BCR::ABL1 transcript by quantitative reverse transcription polymerase-chain reaction at a sensitivity of 0.01%). Maintenance therapy consisted of daily ponatinib and vincristine-prednisone monthly for 2 years, followed by daily ponatinib indefinitely. Twelve intrathecal injections of cytarabine alternating with methotrexate were given as central nervous system prophylaxis. The trial is registered on clinicaltrials.gov with the identifier NCT01424982. Eighty-six patients were treated. Their median age was 46 years (range, 21-80). All 68 patients with active disease at the initiation of therapy achieved complete response (CR) The cumulative CMR rate was 86%. Twenty- patients (23%) underwent allogeneic SCT. With a median follow-up of 80 months (range, 16-129 months), the estimated 6-year event-free survival rate was 65% and the overall survival rate was 75%. There was no difference in outcome by performance of allogeneic SCT in first CR. Common grade 3-5 adverse events included infection (n = 80, 93%), increased liver transaminases (n = 26, 31%) and total bilirubin (n = 13, 15%), hypertension (n = 15, 17%), pancreatitis (n = 13, 15%), hemorrhage (n = 12, 13%), and skin rash (n = 9, 10%). Two ponatinib-related deaths from myocardial infarction (3%; at months 2.6 and 4.3, respectively; both in CR) in the first 37 patients treated led to the ponatinib dose-modifications mentioned earlier, with no further ponatinib-related deaths observed. The long-term results of ponatinib and hyper-CVAD continue to demonstrate excellent outcome results and acceptable safety data, indicating that this strategy is another standard of care approach in frontline Ph-positive ALL.
引用
- Kantarjian H, Short NJ, Jain N, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023. PMID: 36600670. doi:10.1002/ajh.26816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。